#### Initial Clinical Study of the New CGuard<sup>™</sup> MicroNet<sup>®</sup> covered Carotid Stent: "One Size Fits All"

#### In-vitro testing and initial Clinical Results

Christian Wissgott MD

Institute for Diagnostic and Interventional Radiology/ Neuroradiology, imland Clinic Rendsburg– Academic Teaching Hospital of the University of Kiel

#### Background

One of the main difficulties with carotid artery stenting is optimal sizing

- Diameter differences between the common carotid artery (CCA) and the internal carotid artery (ICA)
- Fluoro measurements often give significant diameter errors due to projection differences

Appropriate sizing is fundamental for optimal stent results

- A gap in the contact between the endothelium and the stent may prolong the endothelialisation period, hence undersized stents may lead to complications
- Excessive radial force may stimulate intimal proliferation, whilst oversized stents may promote restenosis

# Background



# Background



The **10 mm CGuard™ EPS MicroNet®** covered stent with **SmartFit™** technology is characterized by its ability to conform to different diameters with an almost equivalent radial force between 5.5 mm to 9.0 mm expansion diameters

# **Study Aim**



To evaluate the mechanical properties and initial clinical results of the CGuard<sup>™</sup> EPS MicroNet<sup>®</sup> covered stent (InspireMD, Inc) designed for:

- Constant radial force at different diameters
- The new ability to self-adjust to different vessel diameters

## In vitro Materials and Methods

 Radial force was determined with a segmented head radial force test device

(Blockwise Engineering LCC, Tempe, Arizona, USA)

- CGUARD EPS with SmartFit 10x 40 mm (InspireMD Inc, Tel Aviv Israel)
- Radial force was constantly measured while decreasing the diameter of the test device from 10 mm to 5 mm
- Radial resistive force values of CGuard were normalized to device length.



## In Vitro Results

#### Chronic outward force during expansion of CGUARD Stent

Diameter [mm]	Chronic outward force , normalized to stent length [N/mm]	Percentage of max force [%]
5.5	0.330	100
6	0.318	96
6.5	0.307	93
7	0.297	90
7.5	0.282	85
8	0.259	78
8.5	0.237	72
9	0.195	59

#### In vitro Results



The chronic outward force, normalized by stent length, indicates a near-equivalent radial force between the minimal radial force at 9.0 mm (0.195 N/mm) and the maximal radial force at 5.5 mm (0.330 N/mm)

## **Initial Clincal Evaluation**

#### Patient Population (n=30)

Age, mean	72.1 ± 7.7	
Gender, m/f	26m / 4f	
Risc factors		
Art. Hypertension	80.0 %	
Diabetes mellitus	43.3 %	
Hyperlipidemia	56.7 %	
Smoking	63.3 %	
Rankin Scale	$1.4 \pm 0.7$	
Mean Stenosis %	86.3 ± 6.4	
Lesion length, mm	$18.7 \pm 4.4$	
CCA Diameter, mm	8.4 ± 0.6	
ICA Diameter, mm	5.8 ± 0.6	
Stents, n		
10/40 mm	25	
10/30 mm	5	

## **Clinical Case 1**

69 year old male patient with a symptomatic high-grade stenosis of the right internal carotid artery





Image after primary implantation of a 10x40 mm CGuard without predilatation.

Final result after angioplasty with a 5/30 mm balloon showing a perfect wall adjustment.



#### **Clinical Case 2**

59 year old male patient with a symptomatic high-grade stenosis of the right internal carotid artery



Image after primary implantation of a 10x40 mm CGuard without predilatation

Final result after angioplasty with a 5x30 mm balloon showing a perfect wall adjustment



## **Clinical Results**

- 30 consecutive patients were treated and all have completed 6 months FU
- Median procedural time was 37.4±8.7 min
- Median diameter changes in CCA and ICA diameters was 2.6 mm
- 100 % technical success without peri-procedural complications
- No major or minor strokes at 6 months

## **Clinical Results**

- Modified Rankin Scale of the symptomatic patients improved from 1.4 ± 0.7 prior to intervention to 0 post procedure
- DUS indicated all stents and all ECA were fully patent
- peak systolic velocity (PSV) was 75.8±9.1 after 30d
- DWI-MRI from 10 of 30 patients after 30 days and 6 months detected no new ipsilateral lesions

## Conclusions

- Through in vitro bench tests, the new "One Size Fits All" CGuard EPS, demonstrated near flat chronic outward radial force in the range of 5.5 to 9.0 mm diameter.
- In this consecutive series of routine CAS patients, the new "One Size Fits All" CGuard EPS demonstrated it can be safely implanted
- The "One Size Fits All", with the SmartFit technology, adapts well to carotid artery changes in diameter
- The six month clinical and DW-MRI results in this initial cohort of patients treated with the "One Size Fits All" CGuard Eps with SmartFit technology demonstrated prevention of embolic events

# Thank you very much for your attention